DBV Technologies CEO to Present at H.C. Wainwright BioConnect Conference
Event summary
- DBV Technologies CEO Daniel Tassé to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York.
- Presentation scheduled for 9:00 am ET, with a live webcast available on DBV Technologies' Investor Relations website.
- Replay of the event will be accessible on the company’s website for 90 days post-event.
- DBV Technologies focuses on developing the VIASKIN® patch technology for food allergies, currently in clinical trials for peanut allergies in toddlers and children.
The big picture
DBV Technologies' participation in the H.C. Wainwright BioConnect Conference underscores its efforts to engage with investors amid ongoing clinical trials for its VIASKIN Peanut Patch. The company is positioning itself as a leader in non-invasive immunotherapy for food allergies, a market with significant unmet medical needs. The strategic focus on epicutaneous immunotherapy (EPIT) could redefine treatment approaches if successful.
What we're watching
- Clinical Progress
- The pace at which DBV Technologies advances its VIASKIN Peanut Patch through clinical trials will determine its market potential.
- Investor Sentiment
- How Daniel Tassé’s presentation impacts investor confidence in DBV Technologies' long-term strategy and financial health.
- Competitive Positioning
- Whether DBV Technologies can differentiate itself in the crowded biopharmaceutical space focused on allergy treatments.
Related topics